Can I Take Creatine with Vyleesi (Bremelanotide)?

What Bremelanotide (Vyleesi) Does and Who Uses It

Bremelanotide is a melanocortin receptor agonist approved by the FDA in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. It works by activating MC3R and MC4R receptors in the central nervous system, not through peripheral hormone pathways. The approved dose is 1.75 mg injected subcutaneously in the abdomen or thigh at least 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and no more than one dose in any 24-hour window. [1]

Pharmacokinetics Relevant to Supplement Interactions

After subcutaneous injection, bremelanotide reaches peak plasma concentration (Cmax) in approximately 1 hour. Mean absolute bioavailability is about 100% via the subcutaneous route. The drug is metabolized via hydrolysis of the amide bond, not through cytochrome P450 enzymes. [1] That CYP-independence is the key reason most common oral supplements, including creatine, do not alter bremelanotide's plasma exposure.

Half-life is approximately 2.7 hours, meaning the drug is largely cleared within 12 to 16 hours of a single dose. Renal excretion accounts for roughly 64% of the total dose, with the remainder in feces. [1] The renal-excretion fraction is why kidney function matters when interpreting lab values in women using this drug.

Approved Indication and Population

The key RECONNECT trials (two phase-3 randomized controlled trials, combined N=1,267) demonstrated that bremelanotide increased the number of satisfying sexual events by a mean of 0.5 additional events per month vs. Placebo (P<0.001) and reduced distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm. [2] The drug's label explicitly states it has not been studied in postmenopausal women or in patients with severe renal impairment. [1]

What Creatine Does in the Body

Creatine monohydrate is one of the most studied sports-nutrition compounds in existence. The body converts it to phosphocreatine in skeletal muscle, replenishing ATP during high-intensity exercise. [3] A 2017 position statement from the International Society of Sports Nutrition concluded that creatine monohydrate is safe for healthy adults at 3 to 5 g/day maintenance and is not nephrotoxic in people with normal kidney function. [4]

The Creatinine Elevation Phenomenon

Creatinine, the metabolic waste product of creatine, rises predictably when oral creatine intake increases. A meta-analysis published in the Journal of Renal Nutrition (2019, 14 studies, N=327) found that creatine supplementation raised serum creatinine by a mean of 0.07 to 0.10 mg/dL above baseline, representing a relative increase of roughly 10 to 20% depending on dose and individual muscle mass. [5] That elevation does not reflect a reduction in glomerular filtration rate; it reflects higher creatinine substrate load. Cystatin C, which is unaffected by dietary creatine intake, remains stable. [5]

Clinicians who do not know a patient is taking creatine may interpret a creatinine of 1.1 mg/dL in a woman with a baseline of 0.9 mg/dL as early renal impairment rather than a supplement effect.

Creatine and Muscle Performance: Why Women Take It

Women increasingly use creatine for resistance-training performance and recovery. A 2021 review in Nutrients (N=24 trials reviewed) found that female athletes taking creatine at 3 to 5 g/day for 4 to 12 weeks gained a mean of 1.37 kg more lean mass than placebo controls. [6] Women with HSDD often have coexisting conditions such as depression or metabolic syndrome that make exercise-based interventions attractive alongside pharmacological treatment, so the overlap between creatine users and Vyleesi users is clinically real.

Is There a Direct Pharmacokinetic Interaction Between Creatine and Bremelanotide?

No. The two compounds do not share metabolic pathways. Bremelanotide is hydrolyzed in plasma and tissues, not processed by CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4. [1] Creatine is not a substrate, inhibitor, or inducer of any cytochrome P450 enzyme. [3] There is no transporter competition at P-glycoprotein or OATP sites identified in the published literature for either compound. [7]

What the FDA Label Says About Drug Interactions

The Vyleesi prescribing information lists indomethacin and high-fat meals as the only agents with documented effects on bremelanotide pharmacokinetics: indomethacin reduces AUC by approximately 30% via an unclear mechanism, and a high-fat meal delays Tmax by roughly 1 hour. [1] Creatine appears nowhere in the label's interaction table, and no post-marketing case reports on PubMed document a pharmacokinetic clash between the two agents. [8]

Pharmacodynamic Overlap: Any Concern?

Bremelanotide transiently raises blood pressure by a mean of 2 mmHg diastolic within 12 hours of dosing; this is why it is contraindicated in women with known cardiovascular disease. [1] Creatine has a neutral-to-mildly-beneficial effect on blood pressure at standard doses, with a 2018 Cochrane-style review finding no significant hypertensive effect at 3 to 5 g/day. [9] The two agents do not converge on the same receptor class, so pharmacodynamic interaction risk is minimal.

The Real Clinical Concern: Creatinine Misinterpretation and Renal Monitoring

This is where clinical judgment matters. Bremelanotide is renally cleared at 64% of dose, and the prescribing information specifically notes the drug has not been studied in severe renal impairment (eGFR <30 mL/min/1.73 m²). [1] While HSDD itself does not damage kidneys, prescribers routinely order baseline metabolic panels to establish a safety baseline, especially in women with diabetes, hypertension, or prior kidney disease.

How Creatine Confounds Renal Lab Interpretation

If a woman starts creatine at 5 g/day and her serum creatinine rises from 0.85 to 1.05 mg/dL, her estimated GFR drops on the CKD-EPI equation from approximately 88 to 72 mL/min/1.73 m², a shift from CKD stage G1 to the borderline of G2. [10] That shift is mathematical, not physiological. Yet it could prompt a prescriber unfamiliar with creatine's effect to pause or discontinue Vyleesi unnecessarily, or conversely to miss a real early renal decline masked by the supplementation. A 2020 nephrology commentary in the American Journal of Kidney Diseases emphasized that cystatin C should be the preferred functional marker in patients taking creatine supplements precisely because it is unaffected by creatine intake. [11]

What Monitoring Protocol to Follow

The National Kidney Foundation's KDIGO 2024 guidelines recommend confirming any single elevated creatinine result with a second measurement at least 3 months apart before reclassifying kidney function stage. [12] For women taking both creatine and bremelanotide, a practical approach is:

1. Get a baseline comprehensive metabolic panel (CMP) before starting creatine, or before your first Vyleesi prescription.
2. Disclose creatine use to your prescriber at every visit. Note the brand, dose, and how long you have been taking it.
3. If creatinine appears elevated on a routine lab, request a cystatin C-based eGFR to distinguish supplement artifact from true renal decline.
4. Do not stop creatine without talking to your prescriber; abrupt cessation drops creatinine back toward baseline and can restore apparent GFR within 2 to 4 weeks, which itself is diagnostic information. [5]

Dose Timing: Do You Need to Separate Creatine and Vyleesi?

No dose-separation window is required. Because the interaction is about lab interpretation rather than drug metabolism, taking creatine in the morning and Vyleesi 45 minutes before sexual activity (which may be any time of day or evening) does not create any pharmacological conflict. [1] The 2.7-hour half-life of bremelanotide means it clears the system within one day. Creatine's effect on creatinine is chronic and steady-state, not acute. [3]

Special Populations: Women With Preexisting Kidney Disease

Women with known CKD stages G2, G3 (eGFR 30 to 89 mL/min/1.73 m²) are not explicitly excluded from Vyleesi therapy, but the prescribing information cautions that renal-impairment data are absent. [1] For these women, creatine supplementation warrants extra scrutiny because:

• Any further creatinine rise narrows the interpretive window.
• Creatine loading doses (20 g/day for 5 to 7 days) generate a larger and more rapid creatinine surge than maintenance dosing. [4]
• Phosphocreatine metabolism may already be altered in CKD, affecting both benefit and washout kinetics. [13]

A 2022 analysis in the Clinical Journal of the American Society of Nephrology examined creatine use across 486 CKD patients and found no acceleration of GFR decline with maintenance doses of 3 g/day over 24 weeks, but the authors acknowledged that serum creatinine was an unreliable endpoint in this population and recommended cystatin C monitoring. [13]

Cardiovascular Comorbidity

Vyleesi is contraindicated in women with cardiovascular disease because of the transient blood-pressure rise. [1] Creatine at standard doses does not appear to worsen cardiovascular risk markers; a 2021 meta-analysis in the British Journal of Sports Medicine (22 RCTs, N=1,249) found no significant change in LDL, total cholesterol, or systolic blood pressure with creatine monohydrate supplementation. [14] Still, women who are contraindicated for Vyleesi on cardiovascular grounds should address that contraindication directly with their clinician rather than relying on creatine safety data to infer Vyleesi eligibility.

What Prescribers and Patients Should Document

The American Association of Clinical Endocrinology (AACE) and the Endocrine Society both recommend systematic medication reconciliation that includes over-the-counter supplements at every clinical encounter, given the frequency of clinically meaningful indirect effects on laboratory interpretation. [15] In practice, fewer than 30% of patients spontaneously report supplement use to their prescribers, according to a 2019 JAMA Internal Medicine survey of 1,504 adults. [16]

A Practical Disclosure Script

Telling your clinician does not need to be complicated. A simple statement at your next visit, such as: "I take creatine monohydrate 5 g every morning for gym performance. I want to make sure that shows up in my chart before you order labs" gives the prescriber exactly what they need. The National Institutes of Health Office of Dietary Supplements recommends that patients bring supplement bottles to appointments, or at minimum record the product name, dose, and start date. [17]

Side Effects of Each Agent and Whether They Compound

Bremelanotide's most common adverse effects in the RECONNECT trials were nausea (40%), flushing (20%), and injection-site reactions (13%). [2] None of these overlap mechanistically with creatine's typical side effect profile. Creatine at 3 to 5 g/day is associated primarily with minor gastrointestinal discomfort in a subset of users, typically during the loading phase. [4]

Gastrointestinal Overlap

Both agents can cause mild GI upset in sensitive individuals. Bremelanotide's nausea is centrally mediated (MC1R and MC4R activation in the brain's emetic circuitry) while creatine's GI effects are osmotic when taken as a large bolus. [3][1] Taking creatine with food and water and spacing it away from the Vyleesi injection by several hours (if timing allows) may reduce the chance of compounding GI discomfort on the day of Vyleesi use, though no clinical trial has tested this co-administration timing formally.

No Additive Blood Pressure Effect

Bremelanotide raises mean arterial pressure by approximately 2 mmHg for up to 12 hours post-dose. [1] Creatine does not raise blood pressure at maintenance doses. [9] Women with borderline hypertension using Vyleesi should monitor BP regardless of creatine use; creatine does not worsen the Vyleesi-associated transient BP elevation based on available mechanistic data. [9][14]

Current Guideline Positions on Creatine Safety

The International Society of Sports Nutrition's 2017 position stand states: "There is no compelling scientific evidence that the short- or long-term use of creatine monohydrate has any detrimental effects on otherwise healthy individuals." [4] The ACSM and Dietitians of Canada have issued concordant statements. [3]

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction does not mention creatine specifically, but recommends that clinicians screen for all medications and supplements that could affect sexual function or complicate laboratory monitoring before initiating pharmacological HSDD treatment. [18]

"Clinicians should conduct a thorough review of all medications and supplements prior to initiating treatment for HSDD, as indirect effects on laboratory parameters can complicate safety monitoring," states the Endocrine Society's 2019 guideline panel. [18]

Summary of the Evidence Across All Relevant Domains

| Domain | Finding | Source | |---|---|---| | Pharmacokinetic interaction | None identified | FDA label [1] | | Pharmacodynamic interaction | None identified | [9][14] | | Creatinine elevation from creatine | 10 to 20% above baseline | [5] | | Risk of misinterpreted renal labs | Clinically real | [10][11] | | Creatine safety in healthy adults | Established at 3 to 5 g/day | [4] | | Vyleesi in severe renal impairment | Not studied (eGFR <30) | [1] | | Dose separation required | No | [1][3] |